micro-community-banner
 
  • Saved

December 03, 2022
Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials - PubMed

Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36373822/

Background: Migraine is a worldwide epidemic neurological disorder that has a significant influence on the quality of life. Migraine attacks are considered to be related to a calcitonin gene-related peptide (CGRP) signaling molecule, and anti-CGRP medications are used to abort and prevent migraine attacks.


Conclusions: In our study, we found that erenumab, especially at the dose of 140 mg, is an effective and well-tolerated preventive treatment for migraine.


"

  • Saved

December 03, 2022
Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study

Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study

Source : https://www.sciencedirect.com/science/article/abs/pii/S0303846722003924?via=ihub

To identify predictors of acute treatment optimization with prescription drugs among people with episodic migraine. A total of 2896 individuals from the American Migraine Prevalence and Prevention study were included...

/>

Conclusions: Almost half of study respondents were not optimized on their usual prescription acute migraine treatment(s). Predictive models identified several features associated with treatment optimization.


Profile Image
  • Saved

December 03, 2022
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study - The Journal of Headache and Pain

Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study - The Journal of Headache and Pain

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01511-y

Objective HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy of erenumab with topiramate in patients who completed the trial on study medication. Methods Post hoc sensitivity analysis was performed using the full analysis set.


Conclusions: This post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD with an early onset of efficacy."


  • December 03, 2022
    Very important study.
  • November 22, 2022
    Key Points
    • Source: The Journal of Headache and Pain
    • Conclusion: “This post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD [monthly migraine days] with an early onset of efficacy.”
    • HER-MES was the first phase 4 trial that assessed the tolerability and effectiveness of erenumab vs. standard of care (i.e., topiramate). The post hoc analysis shed light on the 50% responder rate and the decrease in MMD.
    • The authors wrote, “Presented data comprised patients who showed efficacy in a dose of 92 mg of topiramate, which is within the recommended range of topiramate for migraine prevention. In addition, the results demonstrated that topiramate was an effective therapy for migraine patients tolerating the drug despite not as efficacious as erenumab.”
  • Saved

December 03, 2022
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study - PubMed

A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36404301/

doi: 10.1186/s10194-022-01514-9. 1 Chinese PLA General Hospital, Beijing, China. [email protected]. 2 Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea. 3 Hebei General Hospital, Shijiazhuang, China. 4 The...


Conclusions: "DRAGON study demonstrated the efficacy and safety of erenumab 70 mg in patients with CM from Asia. No new safety signals were observed during the DBTP compared with the previous trials."


Profile Image
  • Saved

November 27, 2022
Quercetin Attenuates Nitroglycerin-Induced Migraine Headaches by Inhibiting Oxidative Stress and Inflammatory Mediators - PubMed

Quercetin Attenuates Nitroglycerin-Induced Migraine Headaches by Inhibiting Oxidative Stress and Inflammatory Mediators - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36432556/

This study aimed to investigate the antimigraine potential of quercetin in migraine pain induced by nitroglycerin (NTG), 10 mg/kg, intraperitoneal injection in rats. Quercetin was administered orally for 1 week,...


Conclusions: Therefore, it was concluded that quercetin improved the pain behavior of migraine patients in the NTG-induced migraine rat model. Quercetin is thought to have antimigraine effects due to its antioxidant and anti-inflammatory potential. Quercetin may therefore be a novel agent that can treat or prevent migraine pain and associated avoidance behaviors.

Profile Image